UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
|
Date of Report (Date of Earliest Event Reported): |
|
March 16, 2007 |
Inovio Biomedical Corporation
(Exact name of registrant as specified in its charter)
|
Delaware |
|
001-14888 |
|
33-0969592 |
|
(State or other jurisdiction |
|
(Commission |
|
(I.R.S. Employer |
|
of incorporation) |
|
File Number) |
|
Identification No.) |
|
11494 Sorrento Valley Road, San Diego, California |
|
|
|
92121-1318 |
|
(Address of principal executive offices) |
|
|
|
(Zip Code) |
|
Registrant’s telephone number, including area code: |
|
(858) 597-6006 |
Not Applicable
Former name or former address, if changed since last report
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
(b) On March 16, 2007, Robert Goodenow, Ph. D., registrant’s Vice President, Corporate Development and a named executive officer, resigned.
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: March 16, 2007
|
INOVIO BIOMEDICAL CORPORATION |
|||
|
|
|
||
|
|
|
||
|
|
By: |
/s/ |
PETER KIES |
|
|
|
|
Peter Kies, Chief Financial Officer |
3